iSTAR Medical develops MINIject®, a minimally invasive glaucoma surgery (MIGS) implant made from the tissue‑integrating STAR® silicone material. The device enhances natural supraciliary aqueous outflow to provide sustained intraocular pressure reduction in open‑angle glaucoma patients, with a favorable safety profile. MINIject® is commercially available in the EU, UK, Switzerland, and Australia, targeting ophthalmologists and eye clinics seeking long‑term, minimally invasive IOP management solutions.
Funding
$44.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Glaucoma, the leading cause of irreversible blindness, results from impaired outflow of aqueous humor, leading to elevated intraocular pressure (IOP) that damages the optic nerve. Current treatment options often rely on daily eye‑drop regimens or invasive surgeries, which can have limited efficacy, safety concerns, or poor patient adherence.
Solution
iSTAR Medical’s MINIject® is a minimally invasive glaucoma surgery (MIGS) implant designed for patients with open‑angle glaucoma. The device is made from STAR®—a medical‑grade silicone composed of a multi‑channel network of hollow spheres that is soft, flexible, and promotes bio‑integration within the supraciliary space. By enhancing natural aqueous outflow in this space, MINIject® provides sustained reduction of IOP with a favorable safety profile. Clinical data have demonstrated meaningful and durable pressure control, positioning MINIject® as the only commercially available MIGS implant that leverages this tissue‑integrating material. The device is approved for sale in the European Union, the United Kingdom, Switzerland, and Australia.
Target Audience
Primary customers are ophthalmologists and eye clinics performing glaucoma surgery, as well as healthcare systems seeking minimally invasive, long‑term IOP management solutions for open‑angle glaucoma patients.
Features
- MIGS implant constructed from STAR® silicone, featuring a porous network of hollow spheres for flexibility and tissue integration
- Targets the supraciliary outflow pathway to augment natural aqueous humor drainage
- Minimally invasive implantation procedure suitable for office‑based surgery
- Clinically validated to deliver safe, sustained IOP reduction in open‑angle glaucoma patients
- Approved for commercial use in the EU, UK, Switzerland, and Australia